| Active, not recruiting | 3 | 198 | RoW | Olokizumab, Standard therapy | R-Pharm, Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor, Group of companies Medsi, JSС | COVID-19 | 10/22 | 04/23 | | |
NCT06440746: Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases |
|
|
| Recruiting | 2/3 | 116 | RoW | Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL), Artlegia, SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL | R-Pharm International, LLC, R-Pharm, Exacte Labs LLC, Data Management 365, Keystat, LLC | Lung Diseases, Interstitial | 06/26 | 12/26 | | |